Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.